Hormonal
Cellular senescence and the resulting Senescence-Associated Secretory Phenotype (SASP) are primary drivers of chronic low-grade inflammation (inflammaging) in aging, contributing to age-related diseases such as atherosclerosis, cancer, and diabetes.
Aging is associated with the accumulation of senescent cells that secrete inflammatory signals (SASP), contributing to chronic low-grade inflammation. While lifestyle factors like diet and smoking contribute, they are not the sole drivers; internal biological aging processes play a critical role. Emerging research suggests targeting these senescent cells (senolytics) may be a future strategy to reduce inflammation and improve healthspan.
This phenotype of senescent cells is termed the senescence-associated secretory phenotype or SASP, which recently has been proposed as the main origin of inflammaging in both aging and age-related diseases such as atherosclerosis, cancer, and diabetes.
Why this rating
Narrative review summarizing multiple animal models and human observational studies; lacks a single definitive clinical trial for senolytics in general populations.
Source
Source of Chronic Inflammation in Aging
Fumihiro Sanada et al. · Frontiers in Cardiovascular Medicine · 2018
DOI 10.3389/fcvm.2018.00012
More from this paper
- Dysregulation of the gut microbiota (dysbiosis) in the elderly, characterized by decreased diversity and reduced anti-inflammatory bacteria, is a source of chronic low-grade inflammation.Moderate
- Increased levels of coagulation factors (specifically Factor Xa) and the resulting activation of protease-activated receptors (PAR-1/2) contribute to chronic inflammation and cell senescence through the IGFBP-5 pathway.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →